BACKGROUND: Inotuzumab ozogamicin (InO), an anti-CD22 antibody-calicheamicin conjugate, demonstrated superior clinical activity versus standard-of-care (SOC) chemotherapies for relapsed/refractory B-cell acute lymphoblastic leukemia in the phase 3 randomized controlled INO-VATE trial. The authors assessed patient-reported outcomes (PROs) from that study. METHODS: Patients were randomized to receive either InO (1.8 mg/m 2 per cycle for 6 cycles) or SOC (fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor, or ara-C plus mitoxantrone, or high-dose ara-C for 4 cycles) and completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the EuroQoL 5 Dimensions Questionnaires at baseline, on day 1 of each cycle, and at the end of treatment. Treatment differences in PROs were assessed using longitudinal mixed-effects models with random intercepts and slopes. RESULTS: Questionnaire completion rates in the InO (n 5 164) and SOC (n 5 162) arms were 85% and 65%, respectively. Baseline scores were similar between arms. Patients who received InO reported better quality of life (QoL), functioning, and symptom scores (except for constipation and emotional functioning). Least-squares mean (95% confidence interval [CI]) differences in physical, role, and social functioning and in appetite loss were significant (6.9 [95% CI, 1.4-12.3], 11.4 [95% CI, 3.2-19.5], 8.4 [95% CI, 0.7-16.1], and 28.7 [95% CI, 216.0 to 21.4], respectively; all P < .05) and had exceeded the minimally important difference of 5. Mean treatment differences in favor of InO on the EuroQoL visual analog scale and the global health status/QoL, dyspnea, and fatigue scales reached or approached the minimally important difference of 5, although without statistical significance. No dimensions were significantly worse with InO versus SOC. CONCLUSIONS: The current PRO data support the favorable benefit/ risk ratio of InO for the treatment of relapsed/refractory acute lymphoblastic leukemia, with superior clinical efficacy and better QoL.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy with an age-adjusted incidence of approximately 1 or 2 per 100,000 individuals globally, and >6500 new cases are expected to be diagnosed in the United States alone this year. [1] [2] [3] The optimization of chemotherapy for pediatric patients with ALL has resulted in cure rates approaching and even exceeding 90%. 4 However, the treatment of adults with ALL has proven more challenging, and the prognosis for these patients remains significantly inferior to that for younger patients. Although complete remission (CR) rates of 80% to 90% are achieved among adult ALL patients who receive frontline treatment, many of these patients relapse, resulting in low cure rates. 5, 6 Among patients who have relapsed/refractory ALL, the prognosis is particularly poor, with most studies reporting 5-year overall survival rates of 10%. 6, 7 Many patients who relapse do not remit and spend prolonged periods as inpatients with significant toxicity that negatively impacts their quality of life (QoL).
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate targeted to the B-cell surface antigen CD22. 8 InO demonstrated superior clinical activity compared with standard-of-care (SOC) chemotherapies for relapsed/refractory Bcell ALL in the phase 3 INO-VATE trial. 9 In that study, patients who received InO had significantly higher CR rates (81% vs 29%; P < .001), a lower disease burden during remission (78% vs 28% had bone marrow blasts below the threshold for minimal residual disease), and more durable remission (median duration of remission, 4.6 months vs 3.1 months; hazard ratio, 0.55; 95% confidence interval [CI], 0.3-1.0; P 5 .03) compared with patients who received SOC chemotherapy. 9 In addition to improved efficacy, newer targeted agents have the potential to minimize toxicity compared with chemotherapy. 10, 11 In assessing the impact of a new agent, it also is crucial to assess QoL and other patientreported outcomes (PROs). The value of such information in the measurement of a patient's subjective experience is becoming increasingly common during clinical trials as well as in routine care and follow-up. [12] [13] [14] It is apparent that patient QoL can have a prognostic effect among those with solid tumors and hematologic malignancies. [15] [16] [17] However, published data on QoL among adults with ALL at any phase of disease are lacking, although they are being prospectively evaluated in the UKALL601 trial (NCT01616238; clinicaltrials.gov).
Here, we report the impact of treatment with InO or SOC chemotherapy on PROs from the INO-VATE trial in adults with relapsed/refractory B-cell ALL.
MATERIALS AND METHODS

Study Design and Patients
INO-VATE (NCT01564784; clinicaltrials.gov) was a global, open-label, randomized phase 3 study. Eligible patients were aged 18 years with relapsed/refractory (5% bone marrow blasts based on local morphologic analysis), CD22-positive, B-cell ALL who were due to receive either first or second salvage treatment. Patients were randomized 1:1 to receive either InO or investigator's choice of SOC therapies and were stratified based on duration of first remission (<12 or 12 months), salvage treatment phase (1 or 2), and age (<55 or 55 years). Full eligibility criteria and study design details are published elsewhere. 9 The protocol was approved by the independent ethics committee and/or institutional review board at each study center, and the study was conducted in accordance with legal and regulatory requirements and the Declaration of Helsinki. Informed consent was obtained from all patients before any study activities.
Treatment
Patients who were randomized to InO received a starting dose of 1.8 mg/m 2 intravenously in each 21-day to 28-day cycle for 6 cycles (0.8 mg/m 2 on day 1; 0.5 mg/m 2 on days 8 and 15). Patients who were randomized to the SOC arm received 4 cycles of the investigator's choice of fludarabine 30 mg/m 2 daily on days 2-6, cytarabine 2.0 g/m 2 daily on days 1-6, and granulocyte-colonystimulating factor 5 lg/kg daily during a 28-day cycle (FLAG); cytarabine (ara-C) plus mitoxantrone (ara-C 200 mg/m 2 daily on days 1-7; mitoxantrone 12 mg/m 2 daily on days 1-3 during a 15-20-day cycle); or high-dose ara-C (ara-C 3 g/m 2 every 12 hours).
PRO Assessments
Health-related QoL, a secondary objective of the study, was assessed in the intent-to-treat (ITT) population. Patients were to complete the self-administered European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) and the EuroQol Group 5 Dimensions Questionnaire (EQ-5D) predose at baseline (day 1 of cycle 1), on day 1 of each subsequent cycle, and at the end of treatment before any study-related tests and/or discussions of their progress with health care providers. Completion was defined as completing >50% of items on the EORTC QLQ-C30 subscales and 100% of items on the EQ-5D.
The EORTC QLQ-C30 is the core questionnaire for the evaluation of health-related QoL of patients participating in cancer clinical trials. It comprises 30 questions, including 9 multi-item scales and 6 single-item measures (Supporting Fig. 1a ). There are 5 functional scales (physical, role, emotional, cognitive, and social functioning), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, 5 single-item symptom scales assessing other cancer-related symptoms (Dyspnea, sleep disturbance, appetite loss, constipation, and diarrhea), and a single-item scale concerning the perceived financial impact of the disease. [18] [19] [20] Changes of 5 to 10 points on the 1-point to 100-point scales of the QLQ-C30 are considered clinically significant. 21, 22 A recent study further suggests focusing clinical attention on patients who report a decrease 6 points and those who report an increase 3 points on QLQ-C30 domains. 23 The EQ-5D is comprised of the EQ-5D descriptive system and a visual analog scale (EQ-VAS) (Supporting Fig. 1b ). 19 The EQ-5D system measures a patient's health state on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-VAS is used to record a patient's self-rated health on a 20-cm vertical VAS from 0 ("worst imaginable health state") to 100 ("best imaginable health state"). The EQ-5D 3-Level (EQ-5D-3L) health states were converted into a single index value (utility) between 0 and 1 using published, country-specific weights. In the current study, the US weight was used to calculate EQ-5D index scores. Differences of 0.08 for the EQ-5D utility score and of 7 for the
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EQ-VAS are recommended as estimates of minimally important differences (MIDs), defined as the smallest change in score that is perceived by patients as being beneficial or that would mandate treatment modification. 24 
Statistical Analyses
Each scale of the EORTC QLQ-C30 was transformed so that scale scores ranged from 0 to 100. Higher scores represented higher ("better") levels of functioning and QoL or a higher ("worse") level of symptoms/problems.
Least-squares means of postbaseline EORTC QLQ-30 and EQ-5D scores were estimated from longitudinal mixed-effects models with random intercepts and slopes. Treatment, time, treatment-by-time interaction, and baseline scores were covariates. 25 Postbaseline scores were estimated by 4-week intervals. End-of-treatment scores were allocated to the appropriate 4-week time interval based on the time they occurred (eg, week 8). Overall treatment comparisons were estimated at approximately week 9. A restricted maximum likelihood method was used for parameter estimates. Analyses were supportive; P values are descriptive only, without multiplicity adjustments.
Correlations between PRO measures and CR or CR with incomplete hematologic recovery (CRi) included the ITT population from both arms combined. The average score change from baseline for each patient was used to create a single score per patient (responder or nonresponder) per variable (EQ-5D, EQ-VAS, and 15 variables for EORTC QLQ-30). The effect of hospitalizations on PRO changes was similarly analyzed.
RESULTS
Patients and Treatments
Of the 326 patients enrolled as of March 8, 2016, 164 were randomized to InO, and 162 were randomized to SOC (the ITT population) (Supporting Fig. 2 ). Nineteen patients in the SOC arm were randomized but never treated; all patients randomized to InO received study treatment. In total, 154 patients (47%) were from North America, 127 (39%) were from the European Union, and the remainder were from Asia and Australia (45 patients; 14%). Baseline characteristics were generally similar between treatment groups, with the exception of the median peripheral blast count, which was higher for patients in the InO arm ( Table 1 ). The median age was 46.5 years in the InO arm and 47.5 years in the SOC arm. In both arms, most patients were in salvage 1 and had received 1 prior induction therapy. In the safety population (ie, patients who received 1 dose of study treatment), the median duration of treatment was 8.9 weeks (range, 0.1-26.4 weeks) in the InO arm and 0.9 weeks (range, 0.1-15.6 weeks) in the SOC arm. The median follow-up was 7.5 months (range, 0.33-37.75 months) and 5.4 months (range, 0.03-39.75 months), respectively; long-term safety follow-up is ongoing. 
Questionnaire Completion Rates
Among all randomized patients who completed 1 question on the EORTC QLQ-C30 questionnaire, the completion rate was 78% (InO arm, 85%; SOC arm, 65%), and 75% completed all questions (InO arm, 82%; SOC arm, 62%). Among patients who completed all questions, completion rates through cycle 4 were high (80%) in both arms; however, few patients (26 of 136 patients; 19%) in the SOC arm remained on treatment by cycle 2, and only 5 (4%) and 1 (1%) remained on treatment by cycles 3 and 4, respectively. EORTC QLQ-C30 questionnaire completion rates at the end of treatment were lower for both arms but were substantially poorer for patients in the SOC arm (40% vs 65% with InO). Completion rates overall and by cycle for the EQ-5D questionnaire were similar to those for the EORTC QLQ-C30 questionnaire. The most commonly reported reason for noncompletion at each cycle and at the end of treatment was "other, specify"; other options were "physically or mentally unable to complete the questionnaire/assessment," "able to complete the questionnaire/assessment but refused," "missed visit," "lost to follow-up," or "withdrew consent." At the end-of-treatment visit, reasons for noncompletion in the InO and SOC arms, respectively, were "other" (30% vs 43% of patients), "withdrew consent" (1% vs 9%), and "missed visit" (2% vs 3%). No other reasons were reported for noncompletion at the end of treatment.
Baseline Symptom Burden and Functioning Impairment
In general, baseline PRO scores in the ITT population were comparable between the treatment arms, with the following exceptions: role functioning and EQ-VAS were somewhat better in the control arm, and social and cognitive functioning, financial difficulties, and pain were somewhat better in the InO arm ( Table 2 ). Overall global health status for this patient population was poor, averaging 56 on a 100-point scale from the EORTC QLQ-C30 questionnaire, compared with a mean score of 71 (standard deviation, 22.4) among the general population. 26 Social and role functioning also were markedly impaired at baseline, with average scores of 59 and 60, respectively, followed by emotional and physical functioning. Symptom burden also was substantial; the highest mean scores at baseline in both arms were for fatigue (InO arm, 41; SOC arm, 40), followed by financial difficulties, insomnia, pain, appetite loss, and dyspnea.
Treatment Effect on PROs
The least-squares mean differences between treatment arms in postbaseline EORTC QLQ-C30 scores for QoL, functioning, and symptom scales generally numerically favored InO versus SOC therapy, except for constipation and emotional functioning ( Fig. 1) . Results from the EQ-5D questionnaires were consistent with those from the EORTC-QLQ-C30.
The overall health status measurements of global health status/QoL from the QLQ-C30, health state from the EQ-5D VAS, and the EQ-5D index scores all were numerically better among patients in the InO arm versus the SOC arm, although without statistical significance (Fig. 1A) . Among individual functioning scores, physical functioning (least-squares mean difference, 6.9; 95% CI, 1.4-12.3), role functioning (least-squares mean difference, 11.4; 95% CI, 3.2-19.5), and social functioning (leastsquares mean difference, 8.4; 95% CI, 0.7-16.1) were significantly (P < .05) in favor of InO and exceeded the MID of 5 for clinical significance (Fig. 1A) . Among gastrointestinal symptoms, appetite loss (least-squares mean difference, 28.7; 95% CI, 216.0 to 21.4; P < .05) was significantly in favor of InO and exceeded the MID of 5 for clinical significance (Fig. 1B) . Changes over time indicate that the greatest postbaseline improvements with InO were observed by the first cycle of treatment, then remained fairly consistent thereafter. Conversely, changes over time in the SOC group were more drastic (Supporting Fig. 3 ). Symptoms relevant to physical functioning, including dyspnea (least-squares mean difference, 24.7; domains relevant to physical, role, and social functioning included mobility, self-care, and usual activity. All of these produced similar findings, with higher percentages of patients in the InO arm reporting having "no problems" Error bars denote 95% confidence intervals. If multiple answers were provided for a single question on the EORTC QLQ-C30 and EQ-5D instruments, then the more severe answer was counted. If <50% of the constituent items on the EORTC QLQ-C30 instrument had been answered for a multi-item subscale, then that subscale was considered missing. Single-item subscales were considered missing if the constituent item was incomplete. Questions not answered on the EQ-5D were considered as missing items and were neither imputed nor used. InO indicates inotuzumab ozogamicin; SOC, standard of care. Asterisks indicate P < .05; dagger, the 95% confidence interval error bar (20.01 to 0.07) is within the symbol. and lower percentages reporting "some problems" and "extreme problems" compared with those in the SOC arm (Supporting Table 1 ). For pain symptoms, similar proportions of patients reported "no problem" in the InO and SOC arms as measured by the EQ-5D questionnaire, echoing findings from the EORTC-QLQ-C30 pain domain. However, substantially more patients reported having "extreme problems" with pain at the end of treatment in the SOC arm (8%) versus the InO arm (2%). No EORTC QLQ-C30, EQ-5D, or EQ-VAS dimensions were significantly worse in patients who received InO compared with those who received SOC.
Effect of Age, CR/CRi, and Hospitalization on PROs
The PRO scores in patients aged <55 years (InO arm, n 5 104; SOC arm, n 5 103) and those aged 55 years (InO arm, n 5 60; SOC arm, n 5 59) were consistent with those of the overall patient population (Fig. 2) .
Patients aged 55 years in the InO arm reported significantly better outcomes for EORTC QLQ-C30 physical and social functioning, but significantly worse emotional functioning, compared with the same age group in the SOC arm. Scores were compared between all patients who were and were not hospitalized, regardless of treatment arm (Supporting Fig. 4 ). Nonhospitalized patients exhibited improvements from baseline in virtually all domains, including global health status/QoL, functioning, and symptom scores. Conversely, deterioration or minimal changes in these scores were observed among hospitalized patients.
In total, 170 patients achieved CR/CRi, including 120 from the InO arm and 50 from the SOC arm. With 1 exception (constipation) that had no change, all domains in the EORTC QLQ-C30 improved from baseline on the functioning, global health status/QoL, and symptom burden scores in patients who achieved CR/CRi (Fig. 3) . By comparison, nonresponders (n 5 156) generally had no change or worsening of these scores from baseline. Physical, role, dyspnea, and EQ-VAS scores were significantly better among patients who achieved CR/CRi compared with those who did not achieve remission.
DISCUSSION
In the phase 3 INO-VATE study of InO for relapsed/ refractory ALL, patients who had substantial impairment in global health status, functioning, and symptom burden at baseline benefited from treatment with InO and reported better PROs in almost all aspects measured with the EORTCQLQ-C30 and EQ-5D questionnaires. These data support the hypothesis that the efficacy and safety profile of InO translates into better QoL compared with SOC chemotherapies. Patients who received InO reported significantly better appetite, were significantly more ambulatory and able to attend to basic living needs (better physical functioning), and also had greater ability to perform strenuous activities. They also reported significantly fewer limitations in work, other daily activities, hobbies, and other leisure activities as well as less interference with their family and social life. Stratified analyses by age appeared to confirm the robustness of the findings, with patients in the group aged 55 years exhibiting even greater PRO benefit than those in the younger group.
Another targeted immunotherapy for relapsed/ refractory ALL is blinatumomab, a bispecific, anti-CD19, and anti-CD3 T-cell engager. 27 In the phase 3 TOWER study (NCT02013167; clinicaltrials.gov), blinatumomab demonstrated activity in patients with Philadelphia chromosome-negative, relapsed/refractory B-cell ALL, with 44% of patients achieving a CR or CRi after 2 cycles. 28 On the basis of the EORTC QLQ-C30 scores reported for this study, patients who received blinatumomab had significantly delayed times to QoL deterioration versus those who received chemotherapies. 28, 29 However, the chemotherapy regimens in the TOWER study were somewhat different and included FLAG plus idarubicin (FLAG-IDA) and clofarabine-based regimens, which may have contributed to higher rates of toxicity and toxicityrelated deaths among patients who received SOC. In addition, changes from baseline scores were reported only for cycle 1 (the median number of treatment cycles was 2 [range, 1-9 cycles] with blinatumomab), and minimal improvement was observed among blinatumomabtreated patients in the ITT population by the end of the first cycle. 28 This is consistent with its modest clinical efficacy (44% had CR with full, partial, or incomplete hematologic recovery). 28 Improvement in PROs for InO-treated patients appears to be partly explained by the high remission rates achieved in this arm, because patients who achieved CR/ CRi reported better QoL outcomes than nonresponders. Because disease progression often negatively affects QoL, treatments with superior clinical efficacy may result in improved patient QoL in the absence of any significant treatment-related toxicity. Although the small number of patients who achieved CR/CRi in the SOC group precludes any meaningful analyses controlling for CR/CRi rates, the higher rates of remission observed with InO versus SOC therapies likely contributed to the more favorable PROs observed with InO. Because being well and at home is also better preparation for transplantation, another key aspect of the treatment benefit of InO is its simple outpatient administration schedule. Evaluation of the relation between PROs and hospitalization indicated that patients who were hospitalized had lower mean changes from baseline in PRO scores regardless of the treatment received compared with patients who were not hospitalized. This may have been because of the poor disease states, poor responsiveness, and/or tolerability of these patients, which necessitated hospitalization. However, hospitalization itself may have impacted mobility, self-care, and the usual activities of these patients. The observation that appetite loss and certain functioning scores (physical, role, and social) were significantly better with InO may correlate with the lower hospitalization rate associated with this treatment. 30 The finding that InO is administered in an outpatient setting may be an additional benefit in terms of PROs.
Limitations of the current analysis include that this was an open-label study, which could have influenced patient perceptions. Also, patients in the InO arm received study treatment longer and had higher completion rates than those in the SOC arm. This is because of the higher rate of discontinuation in the SOC arm. Because patients who discontinued treatment likely had poorer health, patients who continued treatment were assumed to be in better health. The exclusion from the analyses of more patients in poorer health from the SOC arm likely resulted in better PROs for the SOC arm and an underestimation of the PRO benefit in the InO arm.
The importance of PROs for providing a timely response to patient needs and for optimizing treatment outcomes is well known. 31 In patients with relapsed/ refractory ALL for whom the chance of a cure is modest, QoL considerations are of the utmost importance. Here, we demonstrate that the superior efficacy and favorable toxicity profile of InO versus standard intensive chemotherapies is accompanied by better QoL. These findings further demonstrate the positive benefit-risk profile of InO and support its continued development for the treatment of adults with relapsed/refractory ALL.
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